{"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"groups":[{"description":"Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.","id":"BG000","title":"All Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.5","value":"52.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Caucasian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Multiple Myeloma (MM)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Non-Hodgkin's lymphoma (NHL)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Hodgkin's disease (HD)"}],"description":"One patient with HD was entered into the study even though there was no indication of MM or NHL (an inclusion criteria).","paramType":"NUMBER","title":"Disease Diagnosis","unitOfMeasure":"participants"}]}